A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats

Toxicology

Volumn 179, Issue 3, 2002, Pages 183-196

  Teo, Steve ^a   Stirling, David ^a   Thomas, Steve ^a   Hoberman, Alan ^b   Kiorpes, Anthony ^b   Khetani, Vikram ^a  

^a CELGENE CORPORATION   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Attention deficit hyperactivity disorder; D,L methylphenidate; D methylphenidate; Dexmethylphenidate; Oral gavage; Rat; Sub acute; Toxicity

Indexed keywords

DEXTRO LEVO METHYLPHENIDATE; DEXTRO METHYLPHENIDATE; METHYLPHENIDATE; UNCLASSIFIED DRUG;

ABRASION; ALOPECIA; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BODY WEIGHT; CLINICAL CHEMISTRY; CONTROLLED STUDY; DOSE RESPONSE; ENANTIOMER; FEMALE; HISTOPATHOLOGY; INCIDENCE; MALE; MEASUREMENT; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; RAT; TOXICITY TESTING; TOXICOKINETICS;

ACUTE TOXICITY TESTS; ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; METHYLPHENIDATE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 0037107609     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(02)00338-4     Document Type: Article

References (22)

1. Aoyama T., Kotaki H., Sawada Y., Honda Y., Iga T. Non-linear kinetics of threo-methylphenidate enantiomers in a patient with narcolepsy and in healthy volunteers. Eur. J. Clin. Pharmacol. 44:1993;79-84.
2. Barbarasi W., Katusic S., Colligan R., Oankratz V., Weber K., Mrazek D., Jacobsen S. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based cohort in Rochester Minnesota. Arch. Pediatr. Adolesc. Med. 156:2002;217-224.
3. Ciba Pharmaceutical, 1955. New Drug Application 10-187: Ritalin, Summit, NJ.
4. Diener R. Toxicology of Ritalin. Osman B., Greenhill L., Ritalin, Theory and Patient Management. 1991;35-43 Mary Ann Liebert, New York.
5. Ding Y., Fowler J.S., Volkow N.D., Logan J., Gatley S.J., Sugano Y. Carbon-11-D-threo-methylphenidate binding to dopamine transporter in baboon brain. J. Nucl. Med. 36:1995;2298-2305.
6. 11C)D-threo and L-threo-methylphenidate in the human and baboon brain. Psychopharmocology. 131:1997;71-78.
7. Dunnick J.K., Hailey J.R. Experimental studies on the long-term effects of methylphenidate hydrochloride. Toxicology. 103:1995;77-84.
8. Eckerman D.A., Moy S.S., Perkins A.N., Patrick K.S., Breese G.R. Enantioselective behavioural effects of threo-methylphenidate in rats. Pharmacol. Biochem. Behav. 40:1991;875-880.
9. Greenhill, L.L., 1991. Pharmacologic treatment of attention deficit hyperactivity disorder. In: Shaffer, D. (Ed.), The Psychiatric Clinics of North America, vol. 15, #1, Harcourt Brace Jovanovich, Philadelphia, pp. 1-27.
10. Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, DC, 1996
11. Hungund B.L., Perel J.M., Hurwic M.J., Sverd J., Winsberg B.C. Pharmacokinetics of methylphenidate in hyperkinetic children. Br. J. Clin. Pharmacol. 8:1979;571-576.
12. Kimko H.C., Cross J.T., Abernethy D.R. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin. Pharmacokin. 37:1999;457-470.
13. Luthman J., Fredriksson A., Lewander T., Jonsson G., Archer T. Effects of D-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. Psychopharmacology. 99:1989;550-570.
14. National Toxicology Program (NTP), 1995 Technical report on the toxicology and carcinogenesis studies of methylphenidate hydrochloride in F344/N rats and BGC3FI mice. National Toxicology Program Report NTP-TR 439, NIH Publication #95-3355.
15. Patrick, K.S., Muller, R.A., Gualtieri, C.T., Breese, G.R., 1987a. Pharmacokinetics and actions of methylphenidate. In: Meltzer, H. (Ed.), Psyche-Pharmacology: The Third Generation of Progress. Raven Press, New York, pp. 1387-1395.
16. Patrick K.S., Caldwell R.W. Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphanidate. J. Pharmacol. Exp. Ther. 241:1987b;152-158.
17. Rowland A.S., Umbach D.M., Catoe K.E., Stallone L., Long S., Rabiner D., Naftel A.J., Panke D., Faulk R., Sandier D.P. Studying the epidemiology of attention-deficit hyperactivity disorder: screening method and pilot results. Can. J. Psychiatry. 46:2001;931-940.
18. Sax N.I., Lewis R.J. Dangerous Properties of Industrial Materials. 1989;2369-2370 Van Nostrand Reinnold, New York.
19. Sunohara G.A., Malone M.A., Rovet J., Humphries T., Roberts W., Taylor M.J. Effect of methylphenidate on attention in children with attention deficit hyperactivity disorder (ADHD): ERP evidence. Neuropsychopharmacology. 21:1999;218-288.
20. Szporny L., Gorog P. Investigations into the correlations between monoamine oxidase inhibition and other effects due to methylphenidate and its stereoisomers. Biochem. Pharmacol. 8:1961;263-268.
21. Teo, S., Stirling, D., Hoberman, A., Christian, M., Thomas, S., Khetani, V., 2002. D-methylphenidate and D,L-methylphenidate are not developmental toxicants in rats and rabbits. Teratology, in review.
22. Zuddas A., Anciletta B., Muglia P., Cianchetti C. Attention-deficit/hyperactivity disorder: a neuropsychiatric disorder with childhood onset. Eur. J. Pediatr. Neurol. 4:2000;53-62.